VectorialDATA
Stocks/AXAHY

AXAHY — AXA SA

FinancialsEuropeFranceBlockchain certified

Price when we picked it (Mar 18, 2026)

$45.09

Target: $49.34 (+9.4%)

P/E Ratio

8.4

P/E Forward

8.7

Dividend

5.39%

Market Cap

$94.3B

EPS

$5.36

Consensus

Strong Buy

What they do

AXA is one of the largest insurers in the world. It operates in property and casualty insurance (cars, homes, liability), life and savings insurance, health insurance, and asset management. AXA XL is its global commercial/specialty lines arm. With 156,000 employees and presence in about 50 countries, it is a diversified financial giant.

Why we like it

Trades at just 8.7x forward price vs. profit — incredibly cheap for a dominant global insurer. Dividend (the cash they pay you) of 5.4% backed by a disciplined policy of 75% total payout (60% dividend + annual buybacks). The 'Unlock the Future' plan 2024-2026 targets high growth in earnings per share of 6-8%. Target return on equity of 14-16% and beta of just 0.65 — defensive growth with real upside.

Key Risk

Natural disasters due to climate change can significantly increase claim costs, especially in AXA XL. Complex regulation in over 50 jurisdictions.

This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.

Vectorial Data picked AXAHY on Mar 18, 2026 at $45.09.

Full Research

AXA SA (AXAHY) — Full Research

Price: $45.09 | P/E: 8.4 | P/E Forward: 8.7 | Div Yield: 5.4% | Market Cap: $94.3B


What is AXA?

AXA SA is one of the largest insurers in the world and the #1 in Europe. Headquartered in Paris, France, it operates in about 50 countries with 92 million customers and 156,000 employees. It offers property, life, health insurance, and asset management.

Business Segments

SegmentDescriptionPresence
FranceProperty & Casualty, life, health insurance — domestic marketFrance
EuropeOperations in Germany, Switzerland, Belgium, Italy, Spain, UK, IrelandContinental Europe + UK
AXA XLCommercial and specialty lines (reinsurance, large risks)Global (mainly USA)
AsiaLife, health, P&C insuranceJapan, Hong Kong, Thailand
Africa & EME-LATAMEmerging marketsAfrica, Middle East, Latin America
AXA Investment ManagersInstitutional asset managementGlobal

2025 Results

MetricValue
Revenue~€110B+
Underlying EarningsSolid growth vs 2024
ROE~15% (within the 14-16% target)
Solvency II Ratio~220% (very well capitalized)
Free Cash FlowStrong organic generation

Strategic Plan "Unlock the Future" 2024-2026

  • EPS CAGR target: 6-8% (guiding to the high range for 2026)
  • ROE target: 14-16%
  • Total payout: 75% of profit (60% dividend + buybacks)
  • Organic cash generation: €21B accumulated 2024-2026
  • Focus: Growth in commercial P&C, digital platform, health and employee benefits

Capital Return — Very Generous

  • Forward dividend: $2.44/share (5.4% yield)
  • Policy: 75% total payout
  • Annual buybacks complement the dividend
  • Total shareholder yield: ~7-8% annual estimated

Analyst Analysis

MetricValue
ConsensusStrong Buy
Average Price Target$49.34
High Price Target$58.26
Low Price Target$44.00
Upside to Target+9.4%

Why Do We Like It?

  • Forward price vs. profit of 8.7x — ridiculously cheap for Europe's #1 insurer
  • Dividend of 5.4% — one of the highest in the portfolio, well covered
  • 75% total payout — disciplined policy of returning money to shareholders
  • Beta of 0.65 — less volatile than the market, defensive growth
  • ROE of 14-16% — superior value generation
  • Global diversification — 50 countries, 92M customers, multiple business lines
  • €21B in cash generation over 3 years — cash machine

Risks

  • Natural disasters — climate change increases frequency and severity of claims
  • Complex regulation — operates in over 50 jurisdictions with different rules
  • Borrowing costs — drops in rates can affect investment returns
  • AXA XL big price swings — commercial/specialty lines are cyclical
  • Exposure to emerging markets — political and currency risk

Research date: Mar 18, 2026 | Next review: Sep 2026

This is not financial advice.

More picks in Financials

See all Financials picks →

More picks from France

See all picks from France →
Researched: Mar 18, 2026Updated: Mar 18, 2026Next review: Sep 18, 2026

This is not financial advice. Consult a certified financial advisor.

The author may hold positions in the securities discussed.

Past performance does not guarantee future results.